How Takeda’s CEO transformed the company into a global pharma powerhouse

How Takeda’s CEO transformed the company into a global pharma powerhouse


Takeda Pharmaceuticals, Japan’s largest drugmaker, has undergone a sweeping transformation under CEO Christophe Weber, emerging as one of the world’s leading pharmaceutical companies.

Takeda Pharmaceuticals, Japan’s largest drugmaker, has undergone a sweeping transformation under CEO Christophe Weber, emerging as one of the world’s leading pharmaceutical companies.  

The company’s $62 billion acquisition of U.K.-based Shire Pharmaceuticals in 2019 more than doubled Takeda’s revenue and significantly expanded its presence in the United States, positioning it as a formidable global competitor in the pharmaceutical industry.

“You make an acquisition like that—very large, very impactful—if strategically, you gain a lot from it,” Weber told CNBC’s Christine Tan in the latest episode of “Managing Asia.”

Now operating in approximately 80 countries, Takeda is focusing its efforts on high-impact therapeutic areas such as oncology, rare diseases, gastroenterology and neuroscience. As it enters its next phase of growth, the company is committed to scaling its innovation capabilities and reinforcing its role in shaping the future of global healthcare.

“You want to have a balanced pipeline, some areas are more risky than others. You don’t want to be on zero risk because then you will develop medicines without added value,” Weber said.

Watch the video above to learn more from Christophe Weber about Takeda’s transformation and how the company plans to stay ahead in an increasingly competitive market. 



Source

CNBC Daily Open: U.S. stock indexes charge ahead with three record closes
World

CNBC Daily Open: U.S. stock indexes charge ahead with three record closes

The “Charging Bull” statue at Bowling Green in New York’s Financial District. Drew Angerer | Getty Images Investors continue to pile into stocks, undeterred by a government shutdown or shaky jobs data, with all three benchmarks hitting record highs Thursday. With the Senate not meeting yesterday because of Yom Kippur, the U.S. government stayed shut […]

Read More
Private equity’s retail rush is alarming its institutional backers: ‘Bigger issues down the road’
World

Private equity’s retail rush is alarming its institutional backers: ‘Bigger issues down the road’

SINGAPORE — For decades, private markets have been the preserve of pension funds, endowments and sovereign wealth giants. Now, that exclusivity is fading. More wealthy individuals are getting invited into a once-closed club reserved for long-term investments from large institutions — and that is ruffling feathers. The trend has been described by experts as the […]

Read More
Mega AI deals enable exits for private equity — but fuel ‘frothy’ bubble fears
World

Mega AI deals enable exits for private equity — but fuel ‘frothy’ bubble fears

Aside from pushing stocks to all-time highs, the artificial intelligence boom is also giving private equity funds a boost by thawing the frozen IPO market and providing much-needed liquidity. However, AI is also creating what senior industry figures describe as a “frothy” investment landscape in some corners of the market, making it harder to identify […]

Read More